Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to dissemintate knowledge & skills of Acute Cardiovascular Care
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission: To promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our goal is to reduce the burden in cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our Mission is "to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death"
To improve quality of life and logevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
Working Groups goals is to stimulate and disseminate scientific knowledge in different fields of cardiology.
ESC Councils goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
The session was prepared jointly by the ESC WG on Pulmonary Circulation and Right Ventricular Function and its twin brother from European Respiratory Society. ERS was, represented by Andrew Peacock as Chairmen and two speakers – Ralph Shermuly, and Ronald Oudiz.
Dr Oudiz gave a talk on the comprehensive interpretation of the spiroergometric test with special focus on the role of VE/VCO2 (marker of ventilator inefficiency). He admitted that spiroergometry does not correlate directly with indices of RV function but may still be helpful in assessing its consequences in PAH. Two first lectures dealt with cardiovascular imaging. Prof Habib from Marseille presented contemporary echocardiographic methods useful in the assessment of RV function. He highlighted new prognostic information which could be derived from speckle tracking imaging. During the discussion, tricuspid insufficiency was mentioned as a factor which may blunt the role of some of the echo-derived RV functional parameters, such as TAPSE, RV fractional area change etc.
Anton vonk Nordegraaf from Amsterdam gave an overview of existing evidence on CMR evaluation of the RV in PAH, mostly originating from the trials performed by his own group. Most recent findings include strong adverse prognostic significance of decreasing RVEF, regardless direction of concomitant changes of PVR achieved with therapy or resulting from PAH progression. Also, stepwise changes in RV functional remodeling due to PAH, starting from decreased longitudinal contraction but progressing to interventricular septal hypo/dyskinesis might help in better interpretation of some of the echocardiographic indices, such as TAPSE. Finally, Dr Shermully from Giesen presented new experimental trials assessing possibility of treating RV failure based on pulmonary artery constriction model. Some doubts regarding the validity of such model invariably leading to early death of the experimental animals, not allowing for development of potential adaptive mechanisms, emerged during the discussion. Potential role of beta blockers in early prevention of RV remodeling of failure was not totally excluded as a subject for a future trial. The session was well attended and the audience was quite active in the discussion
The right ventricle in pulmonary hypertension